H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.

H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.

hVEGF-IN-1 represses human VEGF-A translation and shows antitumor activity.

HX600 (HX-600) is a synthetic agonist of RXR-Nurr1 heterodimer complex, also selectively activate NGFI-B/RXR heterodimers.

Hycanthone, the most potent mutagen in a series of nine thiaxanthenones, is a potent inducer of nuclear immunoreactivity to antinucleoside antibodies in HeLa cells.

Hydralazine HCl

Hydrazinocurcumin is a synthetic curcumin derivative that inhibits the proliferation of bovine aortic endothelial cells (BAECs) with IC50 of 520 nM without cytotoxicity, inhibits STAT3 phosphorylation and downregulates an array of STAT3 downstream targets.

Hydrochlorothiazide

Hydrocortisone (Cortisol)

Hydroquinidine is an antiarrhythmic agent.

Hydroxyfasudil Hcl(HA1100 Hcl), metabolite of Fasudil, is a potent Rho-kinase inhibitor and vasodilator.

Hydroxy-Fasudil is a metabolite of Fasudil, acting as a potent Rho-kinase inhibitor and vasodilator.

Hydroxyflutamide (Hydroxyniphtholide)

Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.

Hydroxyprogesterone Caproate is a synthetic progestational agent. It binds to and activates nuclear progesterone receptors in the reproductive system and inhibits ovulation and an alteration in the cervical mucus and endometrium.

Hydroxyurea (Cytodrox)

Hydroxyzine is a histamine H1 receptor antagonist (Ki = 1.9 nM).

Hyoscyamine Sulfate

Hypericin is a photosensitive antiviral with anticancer and antidepressant agent derived from Hypericum perforatum. It can inhibit tyrosine kinases with IC50 of 7.5 μM.

Hypocrellin B is an apoptosis inducer. The hypocrellins are pigments isolated from the fungi Hypocrella bambusae and Shiraia bambusicola. They are used as photosensitizers for photodynamic therapy of cancer.

Hypoxia-inducible factor prolyl hydroxylase inhibitor

HZ05 is a potent DHODH inhibitor with IC50 of 32 nM, accumulates cancer cells in S-phase, increases p53 synthesis, and synergizes with an inhibitor of p53 degradation (Nutlin-3a) to reduce tumor growth in vivo..

HZ-1157 is a novel potent inhibitor of HCV NS3/4A protease; Potent Dengue virus inhibitor

HZ-166 (HZ166) is a GABAA receptor subtype-selective benzodiazepine site ligand with preferential activity at α2- and α3-GABA(A) receptors.

I-191 is a novel potent, selective protease-activated receptor 2 (PAR2) antagonist with pIC50 of 7.2 in cell-based assays.

IAA-94 is an indanyloxyacetic acid blocker of epithelial chloride channels.

IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain.

IACS-10759 is a potent inhibitor of complex I of oxidative phosphorylation (OXPHOS).

IACS-4759 potent, selective aminopyrimidine MTH1 (MutT homolog 1) inhibitor with IC50 of 0.2 nM.

IACS-4759 potent, selective aminopyrimidine MTH1 (MutT homolog 1) inhibitor with IC50 of 0.6 nM.

IACS-7e is a potent TRIM24 bromodomain inhibitor with IC50 of 217.8 nM (TRIM24 ligand displacement)..

IACS-9571 is a potent, selective dual TRIM24-BRPF1 bromodomain inhibitor with Kd of 31 and 14 nM, respectively.

IAXO-102 is a novel selective TLR4 antagonist, negatively regulates non-hematopoietic TLR4 signalling and inhibits experimental AAA development.

Iberdomide (CC-220) is a cereblon modulator in clinical development for systemic lupus erythematosis. Iberdomide exhibits an IC50 of 60 nM in TR-FRET cereblon binding assay.

Iberin, a sulfoxide analogue of sulforaphane, is a naturally occurring member of isothiocyanate family. It inhibits cell survival with an IC50 of 2.3 μM in HL60 cell.

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

IBET151-VHL-PROTAC is a novel PROTAC..

Ibiglustat (Genz-682452,SAR402671), is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor.

Ibiglustat (succinate) is a selective inhibitor of glucosylceramide synthase.

IB-MECA is a potent and selective A3 adenosine receptor agonist (Ki values are 1.1, 54 and 56 nM for A3, A1 and A2A receptors respectively).

IBMX(NSC165960; SC2964) is a competitive nonselective PDEs inhibitor with IC50 of 2-50 uM but does not inhibit PDE8 or PDE9; nonselective adenosine receptor antagonist.

IBR2 is a novel small molecule RAD51 inhibitor that specifically binds to RAD51 and disrupts the BRC repeats of BRCA2/RAD51 interaction with IC50 of 0.11 uM.

I-BRD9 is a potent and selective BRD9 inhibitor (pIC50 = 7.3). Exhibits >70-fold selectivity for BRD9 over a panel of 34 other bromodomains and >700-fold selectivity over the BET family.

IBS003031 (IBS-003031) is a novel chemical Yes-associated protein 1 (YAP1) activator, up-regulates H2B-mCherry expression at 1 and 3 uM in mCherry signal based reporter assays.

Ibudilast(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor which has been marketed for treating asthma,ibudilast (MN-166) is tested to treat acute respiratory distress syndrome (ARDS) associated with Covid-19.

Ibufenac is an analog of the NSAID ibuprofen that inhibits COX-1 and -2 activity with IC50 values of 17.4 and 13.1 µM, respectively.

Ibulocydine is the prodrug of CDK inhibitor BMK-Y101, inhibits CDK7 and CDK9 with IC50 of 530 nM and 85 nM in kinase assays, respectively.

Ibuprofen (Motrin) is an anti-inflammatory inhibitor targeting COX-1 and COX-2, of which is used for pain relief, fever reduction and for reducing swelling.

Ibutamoren mesylate (MK-0677) is an orally active nonpeptide growth hormone (GH) secretagogue.

Ibutilide Fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.

IC 86621 is a potent DNA-PK inhibitor with IC50 of 135 nM, also inhibits p110β (IC50=135 nM), less potent for p110α/γ/δ (IC50=880-1,400 nM).

IC 87361 is a potent and selective DNA-PK inhibitor with IC50 of 34 nM, shows >50-fold selectivity over p110β.

IC261 is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.

IC-87114 was the first isoform-selective PI3K inhibitor. p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).

IC-9564 (AIDS033640) is a betulinic acid derivative and potent HIV entry inhibitor that blocks HIV-1 envelope-mediated membrane fusion with IC90 of 0.22 uM for NL4-3 strain.

ICA 069673 is a potassium channel opener with selective action for KCNQ2 and KCNQ3 (EC50=0.69 μM). No meeasurable activity was displayed over a variety of cardiac ion channels.

ICA-1(ICA-1T)is a potent, specific inhibitor of Protein Kinase C-iota (PKC-ι) with IC50 of 0.1 uM, does not inhibit PKC-ζ, the closely related atypical PKC family member.

ICA-121431 is a potent, selective inhibitor of the human Nav1.3 and Nav1.1 voltage gated sodium channels (IC50 = 19 nM) with little or no activity against human Nav1.5 or Nav1.7 channels.

ICA135 (ICA-135, ICA 135) is a broad-spectrum inhibitor against human enteroviruses that inhibits Coxsackievirus A10 (CV-A10) replication in RD cells with IC50 of 1.446 uM.

Icariside I is a metabolite of Icarlin, which could regulate bone remodeling and is recognized as an effective agent for the treatment of osteoporosis.

Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.

I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC50 = 0.142 and 0.625 μM, respectively).

ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.

ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro

ICI-118,551 is a selective beta-2 (β2) adrenergic receptor antagonist.ICI binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor.

Icilin is a synthetic super-agonist of the transient receptor potential M8 (TRPM8) ion channel.

Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).

Icotinib(BPI-2009) is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).

iCRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT) (IC50 = 40.3 nM in assays of Wnt pathway activity).

iCRT3 is an inhibitor of both Wnt and β-catenin-responsive transcription.

iCRT-5 is a selective, cell-permeable β-catenin responsive transcription (CRT) inhibitor with IC50 of 18 nM.

ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.

ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.

Idarubicin Free Base is an orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.

Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor.

IDD388 is a potent aldose reductase (ALR2 or AKR1B1) inhibitor with IC50 of 0.4 uM, shows weak inhibition for AKR1B10 (IC50=4.4 uM)..

IDE-1 induces definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 125 nM).

IDE-2 is a cell-permeable inducer of definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 223 nM for induction of Sox17 expression in ESCs).

Idebenone

IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65 μM.

IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant IDH1 inhibitor with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1R132H, IDH1R132C, and IDH1WT, respectively. Anticancer activity.

IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.

IDH889 is a potent and selective inhibitors of IDH1. IDH899 shows IDH (R132H) IC50 = 20 nM; Cell 2-HG IC50 = 14 nM.

IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM).

IDO-IN-2 is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1, has IC50 values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell.

IDRA-21 is a positive allosteric modulator of the AMPA receptor (AMPAR).

IDX-17119 is a potent, non-nucleoside, HCV NS5B RdRp inhibitor with IC50 of 0.4 nM in replicon luciferase assay.

IDX-375 is a novel potent, non-nucleoside, allosteric HCV NS5B RdRp inhibitor with IC50 of 15 nM and 5 nM for 1a-H77 HCV NS5B polymerase and 1b-J4 HCV NS5B polymerase, respectively.

IEM 1754 2HBr is a selective AMPA/kainate receptor blockers for GluR1 and GluR3 with IC50 of 6 μM.

IFNAR-IN-1 is a nonpeptidic, small molecule inhibitor of IFN-α and IFNAR interaction, specifically inhibits MVA-induced IFN-α responses by BM-pDCs with IC50 of 2-8 uM..

Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

iGOT1-01 is a small molecule inhibitor of aspartate aminotransferase 1 (glutamate oxaloacetate transaminase 1 (GOT1)) with IC50 of 11.3 uM.

IGS-1.76 is a small molecule inhibitor of human NCS-1/Ric8a interaction with affinity of 1.25 uM (hNCS-1).

Iguratimod is one of a series of 4H-1-benzopyran-4-ones which has potent anti-inflammatory, analgesic and antipyretic activity.

IHVR-19029 is a novel antiviral compound that acts as ER α-glucosidase inhibitor, synergistically inhibits the replication of Yellow fever and Ebola viruses in cultured cells combined with favipiravir (T-705).

IIIC3 (Gallocyanine.

IIIM-290 is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively.

IITZ-01 is a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo.

GDC0214 is a potent, selective inhalable and lung-restricted inhibitor of JAK1 with IC50 of 8.52 nM, displays 6.3/704/28 fold selectivity over JAK2/JAK3/TYK2.

IK1 inhibitor PA-6 is an efficient, specific inhibitor of inward rectifier current (IK1), blocks KIR2.x currents of human and mouse with IC50 of 12-15 nM.

IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.

IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.

IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM.

IKK2-IN-8 is a potent, selective IKK2 inhibitor with IC50 of 6 nM, displays >40-fold selectivity over IKK1 (IC50=230 nM).

IKK2-IN-9 is a potent, selective and orally active IKK2 inhibitor with IC50 of 19 nM, displays 20-fold selectivity over IKK1 (IC50=420 nM).

IKKε-IN-1 is a potent IKKε inhibitor; inhibit the in-situ ΙKΚ ε-mediated phosphorylation of IRF3 with an IC50 value of less than about 100 nM.

Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM.

Iloperidone (Fanapt)

IM176OUT05 is a novel, and safe small molecule that improves the acquisition and maintenance of stem cell pluripotency, inhibits electron transport chain (ETC) in the A549 lung carcinoma cell line with IC50 of 3.2 uM.

Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2.

Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2.

Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

Imazapic is a selective herbicide for both the preand post-emergent control of some annual and perennial grasses and some broadleaf weeds

Imazaquin is an imidazolinone herbicide that effectively controls a broad spectrum of weed species, by inhibiting acetohydroxy acid synthase (AHAS)..

IMB-301 (NSC 301209) is a small molecule inhibitor that target the binding interface of the HIV-1 Vif/hA3G complex, inhibits the replication of HIV-1 in H9 cells (IC50=8.63 uM).

IMD-0354 is a synthetic selective NF-kB inhibitor.

iMDK is a small molecule inhibitor of the growth factor Midkine (MDK) that suppresses the endogenous expression of MDK but not other growth factors such as PTN or VEGF.

Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors(IC50=4.13 nM).

Imidazole is a heterocyclic aromatic organic compound. It can be incorporated into many important biological molecules and acts as a corrosion inhibitor for industrial applications.

Imidazole ketone erastin (IKE, Ferroptosis inducer IKE) is a potent, metabolically stable inhibitor of system xc- and inducer of ferroptosis potentially suitable for in vivo applications.

Imidazole-4(5)-acetic Acid Hydrochloride is a competitive antagonist at GABAC receptors.

Imipenem (MK-0787) is a broad-spectrum, semi-synthetic beta-lactam carbapenem that has broad antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains..

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist and is commonly used topically to treat warts on the skin of the genital and anal areas.

Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.

IMM-01 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 140 nM.

IMM-02 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 99 nM.

IMP-1088 is a novel picomolar dual inhibitor of the human N-myristoyltransferases NMT1 and NMT2

Importazole is an inhibitor of importin-β transport receptors.

Impurity D of Cefoperazone

IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.

IMR-1A is the metabolite of IMR-1. IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μmol/L.

IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.

In contrast to the estrogen receptor (ER) selectivity of (S)-equol , (R)-equol is a weaker ER agonist that binds to ERα and ERβ with Ki values of 27.4 and 15.4 nM, respectively.

Inarigivir(SB-9000) is a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA。

INCB024360 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients.

INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively.

INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.

INCB057643 is a BET inhibitor that binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones.

INCB086550 is an orally available, small molecule inhibitor of PD-L1 with potential immune checkpoint inhibitory and antineoplastic activities. In vitro, INCB086550 selectively and potently blocked the PD-L1/PD-1 interaction, induced PD-L1 dimerization and internalization, and induced stimulation-dependent cytokine production in primary human immune cells. In vivo, INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade. Preliminary data from an ongoing phase I study confirmed PD-L1/PD-1 blockade in peripheral blood cells, with increased immune activation and tumor growth control.

INCB10820 (PF-4178903) is a potent, selective, orally bioavailable dual CCR2 and CCR5 antagonist with binding IC50 of 3.0 nM and 5.3 nM, respectively.

INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase.

INCB3344 is a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor; inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM).

INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist.

Incensole is a diterpene originally isolated from frankincense produced by B. carterii.It inhibits degradation of inhibitor of NF-κB (IκBα) in a concentration-dependent manner in TNF-α-stimulated HeLa cells when used at concentrations ranging from 60 to 1

Indacaterol is an ultra-long-acting β-adrenoceptor agonist with pKi of 7.36.

Indacaterol(Onbrez; Arcapta) is an ultra-long-acting β-adrenoceptor agonist.

Indapamide (Lozol)

Indimitecan (LMP776, NSC 725776) is an anticancer DNA Topoisomerase I (Top1) inhibitor..

Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.

Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia.

Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM.

Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines.

Indolactam V ((-)-Indolactam V) is an indole alkaloid tumor promoter that activates protein kinase C (PKC), binds to PKC regulatory domains of mouse skin PKCη and rat brain PKCγ with Ki values of 3.4 nM and 1 uM, respectively.

Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).

Indomethacin (Indocid, Indocin)

Indoprofen is a non-steroidal anti-inflammatory drug, provide insight into treatments for spinal muscular atrophies.

Indotecan(LMP400) is a novel selective and potent topoisomerase I inhibitor with potential anticancer activitity.

INF39 is an irreversible and noncytotoxic NLRP3 inhibitor.

Inflachromene (ICM) is a microglial inhibitor with anti-inflammatory effects, directly binds high mobility group protein 1 (HMGB1) and HMGB2 and reduces their cytoplasmic accumulation in microglial cells.

Ingenol 3-Angelate is a PKC(protein kinase C)activator; anti-cancer drug and an active ingredient in Euphorbia peplus.

Ingenol 5,20-Acetonide (CAS 77573-43-4)

Ingenol 5,20-Acetonide-3-O-angelate (CAS 87980-68-5)

Ingenol is an extremely weak protein kinase C (PKC) activator.

Ingenol-3,4:5,20-diacetonide (CAS 77573-44-5)

inh-02 (RNF5 inhibitor inh-02) is a novel small molecule inhibitor of E3 ubiquitin ligase RNF5/RMA1.

INH1 is a cell-permeable Hec1 inhibitor, which specifically disrupts the Hec1/Nek2 interaction.

INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC50s of 200 nM and 120 nM for INH in Hela and MB468 cells.

Inh2-B1 (STK1 inhibitor B1) is a novel specific S aureus Ser/Thr protein kinase (STK1) inhibitor with IC50 of 49 uM, directly binds to ATP-binding catalytic domain.

INH6 is a potent Hec1 inhibitor, which specifically disrupts the Hec1/Nek2 interaction and causes chromosome mis-alignment.

Inhibitor of ATP-sensitive K+ channel activity in MIN 6 cells. Has also been shown to bind sulfonylurea receptors as well.

Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.

Inhibitor of plasminogen activator inhibitor-1 (PAI-1)

Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 μM for the inhibition of platelet P-selectin expression on human platelets). Thought to act allosterically. Also inhibits thrombin-induced platelet activation.

Inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active and the biphosphonates are used in disorders affecting the skeleton such as metastatic disease, asteoporosis and Paget's.

Inhibits TNF-α processing. Also a general matrix metalloprotease and TACE inhibitor.

INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.

INK055 is a dual PI3Kg/d inhibitor.

INO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells.

iNOS inhibitor 12 is a potent, highly selective iNOS inhibitor with IC50 of 79 nM, dispalys almost 100-fold selectivity over eNOS and nNOS..

inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties.

Insulin levels modulator could be used to treat diabetes.

INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity.

INT-767 is a potent, selective, dual farnesoid X receptor (FXR) and TGR5 agonist with EC50 of 30 and 630 nM, respectively.

Interferon receptor agonist is an interferonm (IFN) receptor agonist.

Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor is a benzimidazole compound that acts as a cell-permeable, potent selective inhibitor of IL-1 kinases.

Inulin

INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay.

Iodipamide is a tri-iodinated benzoate derivative and ionic dimeric contrast agent used in diagnostic imaging.

Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus, used in research to raise the intracellular level of calcium (Ca2+) and as a research tool to understand Ca2+ transport across biological membranes.

Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus.

Ionophore suitable for the assay of sodium activity in blood, plasma, serum. etc. with a solvent polymeric membrane electrode.

Iopamidol is a nonionic, low-osmolar iodinated contrast agent.

iOWH032 is a novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays.

IOX 2 is a potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) (IC50 = 21 nM). IOX 2 displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases.

IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.

IOX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM).

IP6K1 inhibitor TNP is a potent, selective inositol hexakisphosphate kinase IP6K with IC50 of 0.47 uM (IP6K1), does not inhibit either human or yeast Vip/PPIP5K.

IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).

IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.